Besides, we demonstrated that EGFR-mutant NSCLC treated with neoadjuvant immunochemotherapy might undergo similar immune infiltration and TCR clonal expansion as wild-type LUAD, indicating the clinical feasibility of neoadjuvant immunochemotherapy in localized EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.